Page last updated: 2024-11-05

ticlopidine and Experimental Mammary Neoplasms

ticlopidine has been researched along with Experimental Mammary Neoplasms in 1 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Su, X1
Floyd, DH1
Hughes, A1
Xiang, J1
Schneider, JG1
Uluckan, O1
Heller, E1
Deng, H1
Zou, W1
Craft, CS1
Wu, K1
Hirbe, AC1
Grabowska, D1
Eagleton, MC1
Townsley, S1
Collins, L1
Piwnica-Worms, D1
Steinberg, TH1
Novack, DV1
Conley, PB1
Hurchla, MA1
Rogers, M1
Weilbaecher, KN1

Other Studies

1 other study available for ticlopidine and Experimental Mammary Neoplasms

ArticleYear
The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:10

    Topics: Adenosine Diphosphate; Animals; Arthritis, Experimental; Bone Neoplasms; Bone Remodeling; Bone Resor

2012